SCHEMBL25028729

SCHEMBL25028729

COc1cc2nccc(Oc3c(F)cc(N)c(Br)c3F)c2cc1C(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 8/20 0.52
▸ AURKB Q96GD4 5/20 0.52
▸ MET P08581 5/20 0.52
▸ TEK Q02763 5/20 0.52
▸ AURKA O14965 4/20 0.52
▸ AXL P30530 5/20 0.49
▸ PDGFRB P09619 2/20 0.48
▸ PDGFRA P16234 2/20 0.48
▸ ABL1 P00519 2/20 0.46
▸ LCK P06239 2/20 0.46
▸ LYN P07948 1/20 0.46
▸ RIPK2 O43353 1/20 0.45
▸ ERN1 O75460 1/20 0.45
▸ STK10 O94804 1/20 0.45
▸ MAP3K6 O95382 1/20 0.45
▸ ESR1 P03372 1/20 0.45
▸ RET P07949 1/20 0.45
▸ ADORA3 P0DMS8 1/20 0.45
▸ KIT P10721 1/20 0.45
▸ BCR P11274 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25028726 0.91 KDR (0.55) KDRAURKBMETTEKAURKA
SCHEMBL25028721 0.90 KDR (0.51) KDRAURKBMETTEKAURKA
SCHEMBL25028717 0.90 PDGFRB (0.54) KDRAURKBMETTEKAURKA
SCHEMBL25028724 0.90 KDR (0.54) KDRAURKBMETTEKAURKA
SCHEMBL25029459 0.87 KDR (0.51) KDRAURKBMETTEKAURKA
SCHEMBL25028719 0.85 PDGFRB (0.53) KDRAURKBMETTEKAURKA
SCHEMBL25028733 0.84 KDR (0.52) KDRAURKBMETTEKAURKA
SCHEMBL25028720 0.83 KDR (0.52) KDRAURKBMETTEKAURKA
SCHEMBL25028723 0.83 KDR (0.58) KDRAURKBMETTEKAURKA
SCHEMBL22295397 0.83 KDR (0.57) KDRAURKBMETTEKAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 — — US disclosed
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 — — US disclosed
WO-2023016543-A1 UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MULTIPLE MEDICAL APPLICATIONS THEREOF 上海爱博医药科技有限公司 2023-02-16 — — WO disclosed
WO-2023016540-A1 UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 上海爱博医药科技有限公司 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses ABL1, ERBB2, RET KDR 429/4885AURKB 278/4885MET 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback